The sensitivity of the DermaSensor device for melanoma detection was comparable to that of the participating dermatologists.

DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting.

The sensitivity of the DermaSensor device for melanoma detection was comparable to that of the participating dermatologists. There were no device-related safety issues reported in the study. 

“With melanoma, timing is everything,” says Dr. Harold Rabinovitz, a dermatologist and Mohs surgeon in Plantation, Fla., in a news release. “In the hands of primary care providers, I expect the DermaSensor device to help improve the detection of melanoma. This would result in improved, accelerated referrals to dermatologists, and that could save many Medicare patients’ lives."

The DermaSensor device is designed as an objective, non-invasive tool that can be used by primary care providers during an exam to support the rapid, point-of-care assessment of lesions suggestive of skin cancer. The device was granted FDA Breakthrough Device designation and is currently under review by the US Food and Drug Administration (FDA).

“With compelling clinical evidence in a Medicare population and FDA-breakthrough indication, DermaSensor plans to work directly with the Centers for Medicare & Medicaid Services (CMS) to explore how we can make our skin cancer detection technology accessible to Medicare patients,” says DermaSensor’s CEO, Cody Simmons. “We’re working diligently towards a reality where Medicare patients at the highest risk of skin cancer can receive an AI-assisted skin cancer exam in just a few minutes from the convenience of their local primary care office.”